Shi L, Shi M, Meng F P, Wang F S
Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Zhonghua Gan Zang Bing Za Zhi. 2021 Feb 20;29(2):179-182. doi: 10.3760/cma.j.cn501113-20190325-00094.
Clinically, the incidence of end-stage liver disease including decompensated cirrhosis and liver failure is high, which seriously threatens people's health. The existing comprehensive internal medicine treatment is ineffective, and liver transplantation is still the most effective treatment method. However, the shortage of matching liver donors and other reasons constrain the development of liver transplantation, thus limiting the treatment of patients with end-stage liver disease. In recent years, domestic and foreign scholars have conducted many pre-clinical and clinical trials using a variety of cells, and have achieved certain results, providing a new method for the treatment of end-stage liver disease. This article reviews and discusses the existing problems, research status and application progress of varieties of cell therapy for end-stage liver diseases.
临床上，包括失代偿期肝硬化和肝衰竭在内的终末期肝病发病率较高，严重威胁着人们的健康。现有的综合内科治疗效果不佳，肝移植仍是最有效的治疗方法。然而，匹配肝脏供体的短缺等原因制约了肝移植的发展，从而限制了终末期肝病患者的治疗。近年来，国内外学者使用多种细胞进行了许多临床前和临床试验，并取得了一定成果，为终末期肝病的治疗提供了新方法。本文综述并讨论了终末期肝病各种细胞治疗存在的问题、研究现状及应用进展。
